Press Releases BioAtla, Inc.

Equities

BCAB

US09077B1044

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-17 pm EDT			5-day change	1st Jan Change
2.83 ^USD	-8.71%		+4.43%	+15.04%

May. 15	Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Wednesday Ahead of Key Inflation, Retail Data	MT
May. 15	BioAtla Shares Jump 10% in Premarket Activity Wednesday as Diluted Net Loss Narrows in Q1	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

BioAtla : BCAB_Corp_Update_May 2024_FINALv3	May. 14	PU
BioAtla Reports First Quarter 2024 Financial Results and Highlights Recent Progress	May. 14	AQ
BioAtla to Participate in the Citizens JMP Life Sciences Conference	May. 08	AQ
BioAtla to Announce First Quarter 2024 Financial Results and Provide Business Highlights on May 14, 2024	May. 07	AQ
BioAtla Announces FDA Clearance of Investigational New Drug Application for BA3361, a CAB-Nectin-4 Antibody Drug Conjugate for the Treatment of Multiple Tumors	May. 06	AQ
BioAtla Announces Upcoming Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting	Apr. 24	AQ
BioAtla Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress	Mar. 26	AQ
BioAtla to Announce Fourth Quarter and Full-Year 2023 Financial Results and Provide Business Highlights on March 26, 2024	Mar. 19	AQ
BioAtla Announces Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting	Mar. 07	AQ
BioAtla to Participate in the 42nd Annual J.P. Morgan Healthcare Conference	Dec. 20	GL
BioAtla Hosting Virtual R&D Day to Highlight BA3071 CAB-CTLA-4 Phase 1 Data in Multiple Solid Tumor Types	Dec. 13	AQ
BioAtla to Host Virtual R&D Day to Review BA3071 CAB-CTLA-4 Phase 1 Data in Multiple Solid Tumor Types on Wednesday, December 13, 2023	Dec. 06	AQ
BioAtla Presented Phase 2 Clinical Trial Data at the IASLC 2023 North America Conference on Lung Cancer and Virtual KOL Event	Dec. 05	GL
BioAtla Presented Phase 2 Clinical Trial Data at the IASLC 2023 North America Conference on Lung Cancer and Virtual KOL Event	Dec. 05	AQ
BioAtla to Participate in the JMP Securities Hematology and Oncology Summit	Nov. 30	GL
BioAtla to Host Virtual KOL Event to Review IASLC Data on BA3011 in NSCLC	Nov. 28	GL
BioAtla Reports Third Quarter 2023 Financial Results and Highlights Recent Progress	Nov. 07	GL
BioAtla to Participate in the Jefferies London Healthcare Conference	Nov. 06	GL
BioAtla to Participate in the Jefferies London Healthcare Conference	Nov. 06	AQ
BioAtla’s Jay M. Short, Ph.D., Selected for The Explorers Club Lowell Thomas Award	23-10-12	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases BioAtla, Inc.

Equities

BCAB

US09077B1044

Press Releases

Filters